(±)-2-(prop-2-yn-1-yl)tetrahydrofuran | 1698054-31-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: (±)-2-(prop-2-yn-1-yl)tetrahydrofuran
• 英文别名: 2-(prop-2-yn-1-yl)oxolane；2-(prop-2-yn-1-yl)tetrahydrofuran；Propargyl tetrahydrofuran；2-prop-2-ynyloxolane
• CAS: 1698054-31-7
• 化学式: C₇H₁₀O
• 分子量: 110.156
• InChiKey: HJIRCYNVOYQYPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (±)-2-(prop-2-yn-1-yl)tetrahydrofuran 、 7-bromo-3-iodo-N-[(4-methoxyphenyl)methyl]quinolin-4-amine 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 copper(l) iodide 、 三乙胺 作用下， 以58.2%的产率得到7-bromo-N-[(4-methoxyphenyl)methyl]-3-[3-(oxolan-2-yl)prop-1-yn-1-yl]quinolin-4-amine
  参考文献：
  名称：

  WO2019209896A5

  摘要：

  公开号：

  WO2019209896A5
• 作为产物：
  描述：

  2-溴甲基四氢呋喃 、 乙炔锂乙二胺配合物 以 二甲基亚砜 为溶剂， 反应 2.0h， 生成 (±)-2-(prop-2-yn-1-yl)tetrahydrofuran
  参考文献：
  名称：

  [EN] OXAZOLIDINONES AS MODULATORS OF MGLUR5
  [FR] OXAZOLIDINONES UTILISÉES EN TANT QUE MODULATEURS DE MGLUR5

  摘要：

  该披露通常涉及到公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是mGluR5受体的配体、激动剂和部分激动剂，可能对中枢神经系统的各种疾病的治疗有用。

  公开号：

  WO2015054103A1

文献信息

• Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties
  作者：Ganesha Rai、Daniel J. Urban、Bryan T. Mott、Xin Hu、Shyh-Ming Yang、Gloria A. Benavides、Michelle S. Johnson、Giuseppe L. Squadrito、Kyle R. Brimacombe、Tobie D. Lee、Dorian M. Cheff、Hu Zhu、Mark J. Henderson、Katherine Pohida、Gary A. Sulikowski、David M. Dranow、Md Kabir、Pranav Shah、Elias Padilha、Dingyin Tao、Yuhong Fang、Plamen P. Christov、Kwangho Kim、Somnath Jana、Pavan Muttil、Tamara Anderson、Nitesh K. Kunda、Helen J. Hathaway、Donna F. Kusewitt、Nobu Oshima、Murali Cherukuri、Douglas R. Davies、Jeffrey P. Norenberg、Larry A. Sklar、William J. Moore、Chi V. Dang、Gordon M. Stott、Leonard Neckers、Andrew J. Flint、Victor M. Darley-Usmar、Anton Simeonov、Alex G. Waterson、Ajit Jadhav、Matthew D. Hall、David J. Maloney

  DOI：10.1021/acs.jmedchem.0c00916

  日期：2020.10.8

  of compounds, using structure-based design concepts, coupled with optimization of cellular potency, in vitro drug–target residence times, and in vivo PK properties, to identify first-in-class inhibitors that demonstrate LDH inhibition in vivo. The lead compounds, named NCATS-SM1440 (43) and NCATS-SM1441 (52), possess desirable attributes for further studying the effect of in vivo LDH inhibition.

  乳酸脱氢酶（LDH）催化丙酮酸向乳酸的转化，同时还原的烟酰胺腺嘌呤二核苷酸的氧化是糖酵解途径的最后一步。糖酵解在癌细胞的代谢可塑性中起重要作用，长期以来一直被认为是潜在的治疗靶点。因此，LDH的有效的选择性抑制剂代表了一种有吸引力的治疗方法。然而，迄今为止，药理剂未能实现体内显着的靶标结合，可能是因为蛋白质以非常高的浓度存在于细胞中。我们在此报告了一项领先的优化运动，该研究使用基于结构的设计概念，重点研究了吡唑基系列化合物，并在体外优化了细胞效能药物-靶标的停留时间和体内PK特性，以鉴定可证明LDH在体内具有抑制作用的一流抑制剂。名为NCATS-SM1440（43）和NCATS-SM1441（52）的先导化合物具有进一步研究体内LDH抑制作用所需的属性。
• SUBSTITUTED CYCLOALKENE DERIVATIVE
  申请人：Kimura Tomio

  公开号：US20090233952A1

  公开（公告）日：2009-09-17

  [Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation. [Solution] A compound represented by the general formula (I): wherein X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A (the ring is 3- to 7-membered heterocyclyl ring or 3- to 7-membered cycloalkyl ring), each represents a hydrogen atom, or X and Y together represent a substituent of ring B. l and m, independently from each other, represent an integer of 0 to 3, and l+m is 1 to 3. R 1 is an aliphatic hydrocarbon group and the like which may be substituted with a group selected from Substituent group β and Substituent group γ. n represents an integer of 0 to 3. R 2 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. R 3 is a phenyl group, 5- to 6-membered heteroaryl group and the like which may be substituted with a group selected from Substituent group ε. R 5 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. Provided that in the case where R 3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and Y together represent a substituent of ring B.

  [目的] 提供一种替代环烯烃衍生物，具有抑制内毒素诱导的细胞内信号传导或细胞活化并抑制细胞对细胞内信号传导和细胞活化的反应，例如过量生成TNF-α等炎症介质，其药理学上可接受的盐，包含其作为活性成分的药物，其制备方法以及含有上述替代环烯烃衍生物作为活性成分的药物，其在预防和/或治疗与内毒素诱导的细胞内信号传导或细胞活化以及对细胞内信号传导和细胞活化的反应有关的疾病，例如败血症（败血性休克，弥漫性血管内凝血，多器官衰竭等）方面具有优越性。 [解决方案] 一种由通式（I）表示的化合物：其中，X和Y表示与它们结合的碳原子形成环A（环为3-至7成员的杂环或3-至7成员的环烷基环）的基团，每个表示氢原子，或X和Y一起表示环B的取代基。l和m，独立地，表示0至3的整数，且l+m为1至3。R1是脂肪烃基等，可以被从取代基组β和取代基组γ中选择的基团取代。n表示0至3的整数。R2是C1-C6烷基等，可以被从氢原子和取代基组β中选择的基团取代。R3是苯基，5-至6成员的杂环基等，可以被从取代基组ε中选择的基团取代。R5是C1-C6烷基等，可以被从氢原子和取代基组β中选择的基团取代。但在R3是苯基且可以被从取代基组ε中选择的基团取代的情况下，X和Y表示与它们结合的碳原子形成环A的基团，或X和Y一起表示环B的取代基。
• Novel Lactams And Uses Thereof
  申请人：Becker Christopher

  公开号：US20080076752A1

  公开（公告）日：2008-03-27

  Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid β protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit γ secretase and thereby inhibit the production of amyloid β protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.

  具有公式（I）的化合物，包含它们的制药组合物以及它们的使用方法，用于治疗与淀粉样β蛋白产生有关的神经系统疾病和神经系统疾病，例如阿尔茨海默病。这些化合物抑制γ-分泌酶，从而抑制淀粉样β蛋白的产生，从而防止淀粉样蛋白的神经沉积的形成。
• OXAZOLIDINONES AS MODULATORS OF MGLUR5
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160237072A1

  公开（公告）日：2016-08-18

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及I式化合物及其盐，以及使用这些化合物的组合物和方法。这些化合物是mGluR5受体的配体，激动剂和部分激动剂，并且可能对治疗中枢神经系统的各种疾病有用。
• NLRP3 MODULATORS
  申请人：Innate Tumor Immunity, Inc.

  公开号：EP3784670A1

  公开（公告）日：2021-03-03